Crossmark

Efficacy and safety of trastuzumab emtansine versus trastuzumab deruxtecan in HER2-positive breast cancer with anti-HER2 therapy resistance: a multicenter retrospective study

Crossref DOI link: https://doi.org/10.1038/s41598-026-64365-3

Published Online: 2026-07-30

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Xu, Rongbin

You, Jie

Zhang, Xinqian

Zheng, Yuping

Qiu, Qi

Fang, Xiexi

Liu, Li
License Information

Text and Data Mining valid from 2026-07-30

Accepted Manuscript valid from 2026-07-30
More Information

Article History

Received: 8 April 2026

Accepted: 24 July 2026

First Online: 30 July 2026

Declarations

Competing interests: The authors declare no competing interests.

Ethical approval: This study was approved by the Ethics Committee of Linyi people’s Hospital, Sir Run Run Shaw Hospital, Zhejiang Provincial People’s Hospital, Taizhou Central Hospital, Ningbo No.2 Hospital and all procedures were performed in accordance with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

Consent to participate: The requirement for written informed consent was waived by the Ethics Committee of Linyi Cancer Hospital due to the retrospective nature of the study.

Consent to publish: Not applicable as no identifiable personal data or images of participants are present within the manuscript.

Document is current

Any future updates will be listed below